Autolus Therapeutics

Autolus Therapeutics is a pioneering biotechnology company focused on revolutionizing cancer treatment through the development of precisely targeted, controlled, and highly active T-cell therapies. Autolus Therapeutics is dedicated to engineering next-generation, programmed T-cell therapies that enhance the body's ability to recognize, combat, and eliminate cancer cells.

With a robust pipeline of product candidates, Autolus Therapeutics is committed to addressing both hematological malignancies and solid tumors. Through the application of proprietary and modular T-cell programming technologies, Autolus Therapeutics aims to break down cancer's defense mechanisms and provide innovative solutions for patients in need. The primary address of Autolus Therapeutics is Autolus Limited, London, W12 7RZ, GB; the company also has a location in Hertfordshire, UK SG1 2FX, GB.

Autolus Therapeutics is driven by a mission to transform the future of cancer treatment. We invite the management team at Autolus Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further highlight the company's groundbreaking work and commercial potential.